Announcement of Milestone Achievement in Collaboration with Kyoritsu Seiyaku Corporation

Mabgenesis announces a milestone achievement in the development of novel therapeutic monoclonal antibodies based on the collaboration agreement Kyoritsu Seiyaku Corporation headquartered in Tokyo, a global leader in animal health.